The Potential of Psychedelics for the Treatment of Neuropsychiatric Disorders
There is renewed interest in developing psychedelics such as psilocybin, LSD, or MDMA as potential treatments for mental health disorders, including major depression, post-traumatic stress disorder, and anxiety. This presentation will explain the different types of psychedelics that are being investigated as potential drugs, provide an overview of their long history of use, and present current efforts to bring these potential drugs to the clinic with an emphasis on the pharmacology and current understanding of the mode of action as well as the ADME properties of these compounds. Lastly, we will briefly touch on potential challenges. Key concepts discussed in this webinar include: • An overview of psychedelics • Pharmacology, mode of action, and ADME properties • Development of the next generation of psychedelics • Clinical trials • Challenges for psychedelic drug development Download the slides: https://info.bioivt.com/psychedelics-... Questions, comments and requests: https://bioivt.com/about/contact-us More information on our research services and test systems: https://bioivt.com/ Other webinars and resources: https://bioivt.com/resources/educatio... Upcoming webinar notifications: https://info.bioivt.com/subscription-... About the Presenter Dr. Tina Mueller is a Scientific Advisor for ADME-Tox Services at BioIVT. She joined BioIVT in 2023 and consults with customers and internal teams on in vitro ADME programs with a focus on in vitro DDI studies and compliance with regulatory guidelines. Tina obtained her PhD in Biochemistry and Microbiology and earned a Master’s in Environmental Sciences from the Swiss Federal Institute of Technology in Zurich, Switzerland. Before joining BioIVT, she was an Associate Director, Research at Cybin, a small biotech company developing new mental health therapeutics based on psychedelics, where she led the company’s research programs from early through late discovery. Additionally, Dr. Mueller served as a Research Associate Professor at Michigan State University, Senior Staff Scientist at Scripps Florida, and Professor for Biomedical Sciences at Keiser University.

Improving In Vivo Predictions from In Vitro Hepatocyte Models

The Promise and Peril of Psychedelic Medicine

OCCUPATIONAL EXPOSOME WEEK 2026: Session 3 | Shift Workers

Advancing DILI Assessment Using Micropatterned Co-Culture Models: HEPATOPAC® and HEPATOMUNE®

Participants' Meeting for 2026

Personal Experience, Benefits & Risks of Psychedelics | Tim Ferriss & Dr. Andrew Huberman

Isolating, Characterizing & Utilizing Exosomes–Therapeutic, Diagnostic & Personal Care Applications

2026 IMGC Webinar Safeguarding Milk Bioactivity

2026 COA Annual Meeting Day 1: Expanding the Toolbox

Early Safety Assessment for Antibody & Bioconjugate Development | Ncardia x Abzena

Quantum Consciousness and the Origin of Life

Non CYP-Mediated Metabolism Pathways and In Vitro Evaluation Strategies

Psychedelics as Medicine 2025 - Inside the Mind of the LSD King: Conversation with Leonard Pickard

Dr. Jarushka Naidoo, Lung

How AI Cracked the Protein Folding Code and Won a Nobel Prize

Tools for Managing Stress & Anxiety | Huberman Lab Essentials

Alzheimer’s Diagnostics: The Critical Role of Specimen Quality, Longitudinality & Data Depth

Webinar: A Nordic revenue guarantee for paediatric phenoxymethylpenicillin

We FINALLY Understand the Power of Psychedelics (...mostly)

